The dental implications of bisphosphonates and bone disease
Alastair Goss2005, Australian Dental Journal
Sign up for access to the world's latest research
checkGet notified about relevant papers
checkSave papers to use in your research
checkJoin the discussion with peers
checkTrack your impact
Abstract
AI
AI
This paper explores the dental implications of bisphosphonates, a medication commonly used for managing bone diseases. The study examines case reports of osteonecrosis of the jaws in patients treated with bisphosphonates, highlighting the need for dental practitioners to be aware of potential complications related to dental extractions and treatment plans for these patients. Recommendations for preventive dental strategies and therapeutic management of avascular necrosis are discussed, emphasizing the importance of dental assessments before, during, and after bisphosphonate therapy.
Key takeaways
- Most of the bisphosphonates available today are used for inhibition of bone resorption in the treatment of bone diseases (Table 1).
- Bisphosphonates act almost exclusively on bone when administered at physiological doses because of specific affinity to bone, where they deposit both in newly formed bone and in proximity to the osteoclasts.
- Overall, bisphosphonates improve the quality of life of patients suffering from abnormal bone resorption by reducing the number of pathological fractures and bone pain.
- 8, These techniques failed to be effective as bisphosphonates involve the whole jaw bone and indeed all of the skeleton whereas radiotherapy affects only the localized field.
- There are important dental implications with patients on bisphosphonates for bone disease but the best practice answers are currently unknown.
Related papers
Osteonecrosis of the jaws associated with the use of bisphosphonates. Discussion over 52 cases
Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2011
Osteonecrosis of the jaws is increasing worldwide in patients treated with bisphosphonates. A retrospective review of 52 patients who were treated during 2007-2010 for bisphosphonate related maxillofacial symptoms of the jaws was conducted. Patient characteristics and other factors that influenced the disease process were studied. Thirteen patients received bisphosphonates for the prevention or treatment of osteoporosis; 39 for preventing bone metastases from malignant tumors. Thirty-six patients were females (age range 32-87 years, median 64 years); 16 were males (age range 30-81 years, median 73.5 years). Bisphosphonate used was ibandronic acid in four cases, alendronate sodium in 14 cases, and zoledronic acid in 34 cases. Mean bisphosphonate treatment period was 22.44 months (95%CI 19.33-25.55). Thirty patients received intravenous, 22 received oral bisphosphonate. The average period until occurrence of maxillofacial symptoms was 6 months (range 0.5-24 months) in subjects with in...
Osteonecrosis of the jaws secondary to bisphosphonate therapy: a case series
The journal of contemporary dental practice, 2008
The objective of this report is to present the clinical experiences of several patients affected with osteonecrosis (ONJ) secondary to bisphosphonate (BP) therapy and to provide a discussion of the specific BPs implicated in this condition. ONJ secondary to BP therapy is becoming an increasingly reported complication following dental therapy. This is particularly true of surgical dental procedures such as extractions. BPs are a class of pharmaceuticals used in the treatment of numerous disorders affecting bone, including osteoporosis, cancer metastases to bone, hypercalcemia of malignancy, and multiple myeloma. Although ONJ is a more recently described phenomenon, it is an emerging problem that may be associated with significant morbidity such as oral dysfunction, impaired eating ability, pain, and compromised esthetics resulting in a poor quality of life in affected patients. This is a description of 13 patients affected with ONJ secondary to BP therapy managed at the Orofacial Pai...
Bisphosphonate-induced Osteonecrosis of the Jaws: Review, Clinical Implications and Case Report
Head and Neck Pathology, 2007
The introduction of bisphosphonates has increased in the last decade following their indication for metastatic bone diseases, osteoporosis, hypercalcaemia of malignancy and Paget’s disease. Although bisphosphonates have been used clinically for more than three decades there have been no documented long-term complications of their effects on the jaws until recently, where there is now growing evidence of the influence of bisphosphonates on osteonecrosis of the jaws. The aim of this paper is to report a case of this newly described complication, to review this phenomenon, including the clinical implications and to reiterate current clinical guidelines for management of patients in which bisphosphonate therapy is indicated. To the best of our knowledge this is the first reported case of bisphosphonate-induced necrosis of the jaw in South Africa.
Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009
Osteonecrosis of the jaw (ONJ) is a devastating side effect of long-term bisphosphonate (BP) use. We present the largest case series from a single department. This case series included 101 ONJ patients. Data on demographics, medical background, type and duration of BP use, possible triggering events, mode of therapy, and outcome were recorded. ONJ was associated with intravenous BPs in 85 patients and with oral BPs in 16 patients. It was diagnosed after 48, 27, and 67 months of pamidronate, zoledronic acid, and alendronate use, respectively. Long-term antibiotics and minimal surgical procedures resulted in complete or partial healing in 18% and 52% of the patients, respectively; 30% had no response. There was no association between ONJ and diabetes, steroid and antiangiogenic treatment, or underlying periodontal disease. Diagnostic biopsies aggravated lesions without being informative about pathogenesis. A conservative regimen is our treatment of choice. Solutions for decreasing mor...
Osteonecrosis of the jaws in 194 patients who have undergone intravenous bisphosphonate therapy in Spain
Medicina Oral Patología Oral y Cirugia Bucal, 2015
Introduction: Osteonecrosis of the jaw (ONJ) is a destructive bone process in patients undergoing bisphosphonate therapy and it is modulated by local and systemic factors. The purpose of this article is to determine the prevalence of ONJ in patients who have undergone intravenous bisphosphonate therapy, and relate the risk factors described to establish a protocol to reduce the risk of developing ONJ. Material and Methods: We performed a retrospective study on 194 patients treated with IV bisphosponates, analyzing clinical and pathological variables. Results: The prevalence of ONJ was 12.9 %. The most remarkable complication was pain, which was reported by 80% of patients. The average age of the patients undergoing bisphosphonate therapy was 68.91 years. Most of non-diabetic patients did not develop ONJ (92.3%) (p=0.048). During bisphosphonate therapy, 3.1% of patients underwent extractions in the same percentage in the maxilla and in the mandible; all of which, except for one patient, developed ONJ (p<0.001). In regards to the periodontal state, 94.3% of patients without periodontal problems did not develop ONJ (p=0.001). Almost 50% of the necrosis were located unifocally on the mandible (p<0.001). The number of affected patients and the aggressiveness of the disease increased significantly three years after starting treatment (p<0.001). Conclusions: Etiology still is a controversial issue and we should focus on known risk factors, such as the development of surgical procedures in patients undergoing bisphosphonate therapy, especially in patients who have already started their treatment, a group in which ONJ prevalence increases. Moreover, a bad periodontal state in
Osteonecrosis of the jaws and bisphosphonates
Current Osteoporosis Reports, 2008
Osteonecrosis of the jaws associated with bisphosphonate therapy was first identified in 2003 as a condition typified by exposed bone that does not heal after 8 weeks. Other signs and symptoms, such as pain and infection, may or may not be present. There is a strong need for consensus on a case definition for this condition. This condition has occurred primarily among cancer patients treated with the aminobisphosphonates zoledronic acid and pamidronate. The etiology of this condition remains unknown; however, oral disease and trauma appear to be important risk factors. This condition appears to be rare in metabolic bone disease and Paget's disease, with an estimated prevalence of approximately 1 per 100,000 person-years. Thus, the benefits of bisphosphonate therapy appear to outweigh the risks. Recommendations have been established for the oral health management of patients with a history of bisphosphonate therapy.
Jaw Osteonecrosis a Risk Factor in Bisphosphonate Therapy - A Dental Concern
Journal of Oral Health and Community Dentistry, 2010
Bisphosphonates are compound used in the treatment of many skeletal disorders such as bone metastases, osteoporosis, Paget's disease, hypercalcaemia of malignancy and bone pain. A new complication of bisphosphonate therapy administration i.e. osteonecrosis of jaw also known as bisphosphonate related osteonecrosis of the jaws seems to be developing. Over suppression of bone turn over is probably the primary mechanism for the development of this condition, although there may be contributing comorbid factors. Complete prevention of this complication is not currently possible. However, preventive dental care reduces this incidence. Conservative debridement of necrotic bone, pain control, infection management, use of antimicrobial oral rinses and withdrawal of bisphosphonates are preferable to aggressive surgical measures for treating this condition.
Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases
American Journal of Otolaryngology, 2009
Purpose: The aim of the present study was to analyze the clinical presentation, risk factors, radiologic features, histopathologic and microbiological findings, treatment, and evolution of bisphosphonate-associated osteonecrosis of the jaws (BONJ). Methods: This study made a retrospective review of 21 patients who underwent treatment and diagnosis of BONJ during 2004 to 2007 in a tertiary health care center reference for 1,100,000 inhabitants. Results: The mean patient age at the time of presentation was 65.1 years. Of the 21 patients observed, 19 (90.4%) were receiving intravenous zoledronate. Of the 21 patients, 15 were treated with bisphosphonates for bone metastasis (71.4%), 5 for multiple myeloma (23.8%), and 1 for rheumatoid arthritis (4.7%). In 17 patients, the lesions occurred in the mandible. Fifteen patients had previous tooth extractions at the same site of bone necrosis. Conclusion: In our series, most patients improved with conservative surgical debridement. Prospective clinical trials would enable clinicians to make accurate judgments about risk, treatment, and outcome for patients with BONJ.
Bisphosphonates and Oral Pathology II. Osteonecrosis of the jaws: Review of the literature before 2005
2000
Bisphosphonates are bone-turnover modulating drugs which are used in the management of a number of bone diseases ranging from osteoporosis to neoplasic pathology-associated osteolysis. In the last years a number of cases of osteonecrosis of the jaws associated with these drugs have been reported. In this review we analyze the cases published in the literature indexed from 2003 to December 2005. During this period 246 cases were reported, being more frequently associated with women in the sixth decade of life. More frequently associated bisphosphonates were the nitrogenated bisphosphonates (pamidronate, zolendronic acid) and the most common oral antecedent was a dental extraction. Nevertheless more than 25% of the cases were spontaneous. The most frequent site was the mandible and most of the cases presented clinical evidence of bone exposure and pain. Different treatments have been proposed with different antibiotic therapies with or without surgery, showing in general terms an uncertain prognosis with low healing rates.
Osteonecrosis of the jaws in patients treated with bisphosphonates. Review of the literature and the Milan experience
2005
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a severe complication seen most frequently in patients on intravenous bisphosphonates treatment for malignant diseases. High potency bisphosphonates are generally implicated and risk factors also include dental extractions. Prevention is of paramount importance. Management is controversial but there is little evidence basis and the consensus is to be conservative. Recent advances in this area are summarised in this concise review.
The Challenge for the Dental Community-Bisphosphonate-Related Osteonecrosis of the Jaw
Bisphosphonates are a synthetic analogue of inorganic pyrophosphates, a potent inhibitor of osteoclast activity. They are used for the treatment of diseases characterized with a high level of bone resorption/multiple myeloma, osteolytic bone metastases, Paget’s disease of bone, fibrous dysplasia, McCune-Albright syndrome, hypercalcemia of tumour origin, etc. They feature slow intestinal absorption; they are excreted by the kidneys and have high affinity to hydroxyapatite crystals. They incorporate into skeletal bones without being degraded. Bisphosphonates attach to calcium in areas of high bone resorption and remain integrated in the bone for more than ten years/for example, the half-life of Alendronate is 12 years. Once administered, they trigger a cascade of biochemical processes resulting in loss of the ability of osteoclasts to resorb bone, or even to apoptosis of osteoclasts. Bisphosphonate therapy may cause some adverse effects/ kidney failure, arthralgia, fever, muscle pain, hypocalcemia and others. Bisphosphonate-related Osteonecrosis of the Jaw (BRONJ) is a severe, group-specific complication associated with the use of bisphosphonates. Most reported cases were caused by intravenous administration of bisphosphonates. There are a few case reports of osteonecrosis of the jaw caused by continuous oral administration. Marx RE [1], was the first to report 36 cases of “painful bone exposure of the lower and upper jaw in patients treated with bisphosphonates - pamidronate and zoledronate”.
Osteonecrosis of the Jaw associated with the Use of Bisphosphonates
World Journal of Dentistry, 2015
The bisphosphonates (BPs) are drugs used to treat metabolic bone diseases involving intense bone resorption. These compounds are capable of altering the bone remodeling by decreasing osteoclast activity. However, the changes that these drugs cause to the bones of patients without a history of cervico-facial radiotherapy can result in a complication called osteonecrosis of the jaw, which is caused by dental surgery, trauma or infections. Osteonecrosis of the jaw is characterized by an exposed necrotic bone in the maxillofacial region, persisting for prolonged periods without complete healing. Based on clinical experience and literature review, the aim of the present study was to describe a clinical case of a patient with osteoporosis taking alendronate (Fosamax®) to control the progression of the disease with a characteristic clinical condition of osteonecrosis of the jaw. We evaluated the etiological factors, the relationship between BPs and osteonecrosis of the jaw, the mechanisms ...
Bisphosphonate and Osteonecrosis of the Jaw: The Oral Surgeon's Perspective
European Journal of Inflammation
Bisphosphonates (BPs) are an important class of drugs, useful in the treatment of some metabolic and oncologic skeletal diseases. BPs have shown a sure effectiveness in the treatment and in the palliative care of such pathologies; on the other hand, an avascular osteonecrosis of the jaws (B-ONJ = Bisphosphonate OsteoNecrosis of the Jaw) has recently been reported as an adverse effect not only of BP intravenous infusions, but also of their prolonged oral administration. B-ONJ normally follows a dental extraction or other surgical procedure in the oral cavity, but it also can develop spontaneously. In the latter case, some systemic risk factors, such as comorbidities and co-therapies or jaw anatomical conditions, can play a leading role in the onset of this pathologic condition. B-ONJ is an uncommon but potentially serious complication of BP therapy that can gravely affect the patient's quality of life, producing significant morbidity. To date, no therapies are completely effectiv...
Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?
Annals of Oncology, 2006
Background: An increasing amount of reports are being published suggesting a relationship between the use of bisphosphonates (BPs) and the development of osteonecrosis of the jaw (ONJ). We reviewed the currently available evidence and explore the potential mechanisms of action based on the known effects of the concerned BP.
Bisphosphonate-associated osteonecrosis of the jaws: The limits of a conservative approach
Head & Neck, 2009
Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia
Journal of Oral and Maxillofacial Surgery, 2007
, FICD § Purpose: The purpose of this study is to estimate the frequency and describe the clinical characteristics of patients diagnosed with bisphosphonate-associated osteonecrosis of the jaws (ONJ) in Australia. Materials and Methods: Cases of ONJ were identified in 2004 and 2005 primarily by a postal survey of Australian Oral and Maxillofacial Surgeons (OMS) with additional cases from other dental specialists and the Commonwealth of Australia Adverse Drug Reaction Committee (ADRAC). The clinical characteristics were recorded. The frequency of ONJ cases was estimated from prescription and dental extraction data. Univariate and bivariate statistics were calculated. Results: One hundred fifty-eight cases of ONJ were identified. These were primarily in patients with bone malignancy (72%) and the main trigger was dental extraction (73%). The reported number of cases varied between different Australian States with the highest frequency being reported in the States with the best integrated health systems. The frequency of ONJ in osteoporotic patients, mainly on weekly oral alendronate was 1 in 2,260 to 8,470 (0.01% to 0.04%) patients. If extractions were carried out, the calculated frequency was 1 in 296 to 1,130 cases (0.09% to 0.34%). The total dose of oral alendronate at the onset of ONJ was 9,060 (Ϯ7,269) mg. The frequency of ONJ for Paget's disease cases was 1 in 56 to 380 (0.26% to 1.8%). If extractions were carried out, the calculated frequency of ONJ was 1 in 7.4 to 48 (2.1% to 13.5%). The frequency of ONJ in bone malignancy cases, treated with mainly intravenous zoledronate or pamidronate was 1 in 87 to 114 (0.88% to 1.15%). If extractions were carried out, the calculated frequency of ONJ was 1 in 11 to 15 (6.67% to 9.1%) The total dose of pamidronate was 3,285 (Ϯ2,530) mg and zoledronate 62 (Ϯ54.28) mg at the onset of ONJ. The median time to onset of ONJ was 12 months for zoledronate, 24 months for pamidronate, and 24 months alendronate. Conclusions: Before the prescription of bisphosphonates for bone disease the patient should be made dentally fit so that the need for subsequent dental extractions is minimized. Appropriate informed consent for the risk of ONJ for different bisphosphonates, for osteoporosis, and malignancy both in general and in particular for dental extractions can be provided using this data.
A review of bisphosphonate-associated osteonecrosis of the jaws and its management
Journal (Canadian Dental Association), 2007
Bisphosphonate-associated osteonecrosis (BON) may result in serious oral complications, such as osteomyelitis and chronic exposure of necrotic bone. Dentists must be familiar with this disorder and pay special attention to all patients on bisphosphonate therapy due to their defective osteoclast function and reduced osseous tissue vascularity, leading to impaired wound healing. The purpose of this paper is to review the history and pathogenesis of BON, discuss its differential diagnosis, provide guidance to dentists on possible measures to prevent BON and review the management of patients with BON.
Osteonecrosis of the Jaw in Patients undergoing Long-TermTreatment with Bisphosphonates: Incidence and AssociatedCharacteristics
2017
Introduction: Bisphosphonates (BPs) provide a well-known, favorable therapeutic action on the bony tissue of patients receiving these drugs. Aim: The aim of this study is to link long-term treatment with nitrogenous bisphosphonates to ONJBPs (osteonecrosis of the jaw caused by bisphosphonates), the most frequently encountered side effect in jaws. In 2007 the AAOMS defined the concept of ONJBP as "an exposed necrotic bone area in the mouth present for over eight weeks in patients who have undergone longterm treatment with bisphosphonates and who have not received radiation therapy to the head and neck." Subsequently in 2009 the AAOMS defined 4 clinical stages (0 to 3) of ONJBPs. Subjects and methods: Between January 2007 and December 2013 25,538 patients were referred to the Department of Maxillo-facial Surgery and Traumatology II of the School of Dentistry, University of Buenos Aires Argentina. All these patients underwent surgical dental treatment and the 1097 patients fo...
Bisphosphonate-related osteonecrosis of the jaws: A report on 30 cases
Open Journal of Stomatology, 2013
Aim: To report a series of thirty cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Material and Methods: For 30 patients with BRONJ, gender, age, underlying diagnosis, type of bisphosphonate (BP), administration route and duration, location and stage of osteonecrosis, symptoms and oral health status, radiological findings of the jaws, treatment and outcome, were recorded. Results: Underlying diagnoses in the series (12 male; 18 female; mean age 70.50 ± 9.62) were: 12 multiple myeloma, 7 breast cancer, 3 prostate carcinoma, 1 kidney/lung/ bladder/mediastinal cancer, 1 chronic lymphocytic leukemia, 1 osteoporosis, 1 palatal osteosarcoma + osteoporosis, 1 non-Hodgkin’s lymphoma. Forty-seven osteonecrotic lesions were detected; 30 localized in the mandible,17 inthe maxilla; trigger events were tooth extraction in 31 cases (66%), periodontal disease in 4 (8.50%), incongruous dentures in 3 (6.40%), perimplantitis in 1 (2.10%), unknown in 8 (17%). Twenty-nine patients had ...
Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma?
Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 2009
Bisphosphonates are used for the standard of care of patients with skeletal metastases and hypocalcemia of malignancy. Bisphosphonate-induced osteonecrosis (BION) is a serious complication. Clinically, BION presents as an area of exposed alveolar bone that occurs spontaneously or becomes evident following an invasive surgical procedure such as extraction of a tooth, periodontal surgery, apicoectomy, or oral implant placement. The mechanism by which bisphosphonates cause osteonecrosis is uncertain. There are no controlled trials to show a direct cause-effect relationship between bisphosphonates and osteonecrosis of the jaw. Oral bisphosphonate-induced necrosis is a rare clinical entity, less frequent, less aggressive, more predictable, and more responsive to treatment than IV forms of bisphosphonate-related osteonecrosis of the jaw. However, there have been reports of this complication with the less potent oral forms of bisphosphonates (0.007% to 0.01%). The morbidity of osteonecrosis of the jaw induced by IV bisphosphonates is significant, so prevention should receive prime importance. Patients should receive prophylactic dental examinations, and any necessary dental treatment before starting bisphosphonate therapy. Good communication among dentists, oral surgeons, physicians, and oncologists is of vital importance in providing care of these patients.
Cited by
Bisphosphonate-induced Osteonecrosis of the Jaws: Review, Clinical Implications and Case Report
Head and Neck Pathology, 2007
The introduction of bisphosphonates has increased in the last decade following their indication for metastatic bone diseases, osteoporosis, hypercalcaemia of malignancy and Paget’s disease. Although bisphosphonates have been used clinically for more than three decades there have been no documented long-term complications of their effects on the jaws until recently, where there is now growing evidence of the influence of bisphosphonates on osteonecrosis of the jaws. The aim of this paper is to report a case of this newly described complication, to review this phenomenon, including the clinical implications and to reiterate current clinical guidelines for management of patients in which bisphosphonate therapy is indicated. To the best of our knowledge this is the first reported case of bisphosphonate-induced necrosis of the jaw in South Africa.
Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management
Expert Opinion on Drug Safety, 2008
Background : Bisphosphonates are widely used for the treatment of bone diseases. Bisphosphonate-associated osteomyelitis of the jaw (BAOMJ) affects 1 per 100,000 patients-treated years for non-cancer bone diseases and ∼ 1-2% of cancer patients treated with bisphosphonates. Results : The mechanism of sustaining osteonecrosis of the jaw (ONJ) is unclear, but several predisposing factors have been identified. The dosage, frequency of administration and the duration of bisphosphonate therapy may precipitate BAOMJ. Conclusion : Evidence supports immune and infectious etiology for BAOMJ. Hence, the term BAOMJ seems more appropriate than ONJ or BAON (bisphosphonate-associated ONJ). Bisphosphonates are the mainstay of therapy for osteoporosis. Cancer patients receive 10-15 times higher doses of bisphosphonates at a greater frequency per year than osteoporosis patients. This may trigger BAOMJ in such patients. The benefits of bisphosphonate therapy outweigh the incidence and risks of BAOMJ. Bisphosphonates show a temporal association with BAOMJ and no direct causal relation with ONJ.
Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma
Dentistry Journal, 2016
Medication-related osteonecrosis of the jaw is a known side-effect of antiresorptive therapy in patients with malignant diseases. Nevertheless, the exact pathogenesis is still unknown and published prevalences show a significant range. The aim of the presented paper was to assess the prevalence of osteonecrosis (ONJ) in breast cancer, prostate cancer, and multiple myeloma patients receiving parenteral antiresorptive therapy. For this reason a PubMed search was performed and 69 matching articles comprising 29,437 patients were included in the analysis. Nine-hundred fifty-one cases of jaw necrosis were described. The overall ONJ-prevalence was 2.09% in the breast cancer group, 3.8% in the prostate cancer group, and 5.16% for multiple myeloma patients.
Bisphosphonate Related Osteonecrosis of the Jaw: An Update
Journal of Maxillofacial and Oral Surgery, 2013
Objectives The aim of this paper is to summarize different diagnostic criteria as well as probable aetiopathogenesis of bisphosphonates related osteonecrosis of the jaw. The electronic search of peerreviewed journals were performed in MEDLINE (PubMed) database in order to find the relevant articles on bisphosphonates related osteonecrosis of the jaw (BP-related ONJ). The search was restricted to English language articles, published from January 2002 to May 2013. On the basis of these articles, probable aetiopathogenesis and different diagnostic criteria of BP-related ONJ were summarized. Results BP-related ONJ is related to the development of avascular necrosis or dead jaw bones. In recent literature many given hypotheses show the aetiopathogenesis and diagnosis of BP-related ONJ which are interlinked and have multifactorial nature. Their diagnosis revolves around four main diagnostic criteria that differentiate it from other conditions which can delay bone healing. Conclusions Factors like potency of bisphosphonates, biology of jaw bone, antiangiogenic property of bisphosphonates and soft tissue toxicity in combination with present infection, other drugs, pre-existing pathologies, compromised immune response and dentoalveolar trauma may lead to development of BP-related ONJ.
The importance of a thorough medical and pharmacological history before dental implant placement
Australian Dental Journal, 2012
The risk of osteonecrosis in patients treated with bisphosphonates is well known and guidelines intended to prevent this complication have been established and accepted. Bisphosphonate related osteonecrosis of the jaws (BRONJ) is a unique condition in which even past administration of medication may be of current and future relevance. We present a case of BRONJ in the maxilla after dental implant placement. The patient suffered from osteoporosis and had been treated with oral alendronate sodium in the past. However, the medication was stopped two years before implant placement, and the treating dentist was unaware of the patient's past bisphosphonate use. Prevention of BRONJ is based on identifying at-risk patients, and then avoiding or modifying dentoalveolar surgical procedures in these individuals. Nevertheless, there seems to be some difficulties identifying patients at risk. We present some of the challenges that impede thorough assessment of a patient's medical background (review of systems) in the dental office, and suggest possible solutions.
Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures
Asia-Pacific journal of clinical oncology, 2016
Denosumab, a bone-modifying agent, reduces the risk of skeletal-related events in patients with bone metastases from solid tumors and is generally well tolerated. However, hypocalcemia, osteonecrosis of the jaw (ONJ) and atypical fracture are potential and important toxicities of denosumab therapy that require attention. In pivotal phase III trials in patients with bone metastases from solid tumors, the incidence of hypocalcemia was 9.6% in denosumab-treated patients, with most events being asymptomatic, grade 2 and resolving by week 4. Established hypocalcaemia requires additional short-term calcium and vitamin D supplementation and, if severe, administration of intravenous calcium. ONJ was reported in 1.8% of patients receiving denosumab over 3 years in these trials. Involvement of an experienced oro-maxillary surgeon is important if ONJ is suspected. Atypical fractures were rare in a large study of denosumab using the dose and scheduling approved for the treatment of osteoporosis...
Minor post-extraction complications other than BRONJ in older patients on oral bisphosphonates - a retrospective study
Gerodontology, 2016
Minor post-extraction complications other than BRONJ in older patients on oral bisphosphonatesa retrospective study Background: Oral bisphosphonates (BP) have been prescribed widely in osteoporosis patients. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) has been reported as a major complication, but there is little information about minor complications. Objective: This retrospective study describes post-operative complicationsother than BRONJassociated with dental extractions in patients on oral BP and compares outcomes with patients not on oral BP. Methods: The study period was 2004-05 ending December 2005, prior to the introduction of protocols for minimising risks related to extractions in patients on BP therapy. Records of patients aged 60 years and over who underwent extractions during this period at Sydney Dental Hospital were examined and post-operative complications analysed. Results: There were 266 participants identified on oral BP therapy out of an available number of 3811 available files based retrospectively from records of 4126 participants who underwent extractions during the two-year period. In the oral BP group, 10% had complications compared with 2% in the non-oral BP group (p < 0.0001). This relationship remained significant even after adjusting for age, gender, operator, type and site of procedure. Delayed healing (36%) and exposed alveolar bone which required an intervention (31%) were the most common complications in the BP group. Conclusion: The prevalence of minor post-operative complications among BP participants was significantly higher than in non-BP participants. The nature of the complications was in the range of pathology familiar toand treatable bythe general dentist.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.